DeLong Mark Jeffrey, Chief Business and Strategy Officer at Apellis Pharmaceuticals ($APLS), sold shares on the open market four times over the past year, totaling about $147 thousand. His most recent sale occurred on February 11, 2026. These sales rank him 9,012th among 11,678 insiders in our database by total value sold, well below the average of $8.6 million across 6.4 transactions per insider. He made no open market purchases in the last 365 days.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 11, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | S | Common Stock | 368 | $22.15 | 114,591.0000 | 130,067,000 | 0.32% | 0.00% |
| Jan. 28, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | A | Common Stock | 36606 | $0.00 | 114,959.0000 | 130,067,000 | 46.72% | 0.03% |
| Jan. 22, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | S | Common Stock | 3371 | $21.77 | 78,353.0000 | 130,067,000 | 4.12% | 0.00% |
| Jan. 20, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | S | Common Stock | 1334 | $19.79 | 81,724.0000 | 130,067,000 | 1.61% | 0.00% |
| Jan. 13, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | S | Common Stock | 1780 | $22.19 | 83,058.0000 | 130,067,000 | 2.10% | 0.00% |
| June 9, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | A | Stock Option (Right to Buy) | 82500 | $19.39 | 82,500.0000 | 123,905,000 | 9999.99% | 0.07% |
| Feb. 11, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | S | Common Stock | 363 | $28.54 | 83,945.0000 | 123,905,000 | 0.43% | 0.00% |
| Jan. 29, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | S | Common Stock | 365 | $29.52 | 84,308.0000 | 123,905,000 | 0.43% | 0.00% |
| Jan. 22, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | S | Common Stock | 1396 | $30.43 | 84,673.0000 | 123,905,000 | 1.62% | 0.00% |
| Jan. 21, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | A | Common Stock | 28508 | $0.00 | 86,069.0000 | 123,905,000 | 49.53% | 0.02% |
| Jan. 17, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | S | Common Stock | 1235 | $29.96 | 57,561.0000 | 123,905,000 | 2.10% | 0.00% |
| Jan. 13, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | S | Common Stock | 1599 | $28.70 | 58,796.0000 | 123,905,000 | 2.65% | 0.00% |
| Aug. 12, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | M | Common Stock | 5201 | $13.85 | 60,395.0000 | 118,678,000 | 9.42% | 0.00% |
| Aug. 12, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | M | Stock Option (Right to Buy) | 5201 | $0.00 | 14,799.0000 | 118,678,000 | 26.01% | 0.00% |
| March 18, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | S | Common Stock | 9913 | $56.90 | 54,693.0000 | 118,678,000 | 15.34% | 0.01% |
| Feb. 12, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | S | Common Stock | 597 | $67.77 | 64,606.0000 | 118,678,000 | 0.92% | 0.00% |
| Jan. 29, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | S | Common Stock | 367 | $64.14 | 65,203.0000 | 118,678,000 | 0.56% | 0.00% |
| Jan. 22, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | S | Common Stock | 1384 | $65.00 | 65,570.0000 | 118,678,000 | 2.07% | 0.00% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | A | Stock Option (Right to Buy) | 24666 | $66.30 | 24,666.0000 | 118,678,000 | 9999.99% | 0.02% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | A | Common Stock | 16963 | $0.00 | 68,585.0000 | 118,678,000 | 32.86% | 0.01% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | S | Common Stock | 1631 | $66.81 | 66,954.0000 | 118,678,000 | 2.38% | 0.00% |
| Oct. 23, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | S | Common Stock | 131 | $46.04 | 51,622.0000 | 106,114,000 | 0.25% | 0.00% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | F | Common Stock | 441 | $58.50 | 51,341.0000 | 106,114,000 | 0.85% | 0.00% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | A | Stock Option (Right to Buy) | 7489 | $0.00 | 7,489.0000 | 106,114,000 | 9999.99% | 0.01% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | A | Common Stock | 5280 | $0.00 | 51,782.0000 | 106,114,000 | 11.35% | 0.00% |
| Feb. 10, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | F | Common Stock | 670 | $51.21 | 46,502.0000 | 106,114,000 | 1.42% | 0.00% |
| Jan. 27, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | F | Common Stock | 367 | $52.77 | 47,172.0000 | 106,114,000 | 0.77% | 0.00% |
| Jan. 20, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | F | Common Stock | 1149 | $52.05 | 47,539.0000 | 106,114,000 | 2.36% | 0.00% |
| Jan. 12, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | A | Common Stock | 19634 | $0.00 | 48,688.0000 | 106,114,000 | 67.58% | 0.02% |
| Jan. 12, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | DeLong Mark Jeffrey | Chief Business & Strat Officer | A | Stock Option (Right to Buy) | 30845 | $52.66 | 30,845.0000 | 106,114,000 | 9999.99% | 0.03% |